Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 259

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Anthony M. Hunter, Mrinal M. Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes, Yanxia Li, R. Angelo de Claro, Kelly J. Norsworthy, Marc Theoret, Elizabeth Pulte, Eric Padron

Blood (2024) 144 (19): 1987–1992.

https://doi.org/10.1182/blood.2024025648

Published: 2024

Journal Articles

High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

Zhuoer Xie, Jenna Fernandez, Terra L Lasho, Christy M. Finke, Michelle Amundson, Kristen McCullough, Betsy LaPlant, Abhishek A Mangaonkar, Naseema Gangat, Kaaren K Reichard, Michelle Ann Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood blood.2024024962.

https://doi.org/10.1182/blood.2024024962

Published: 2024

Includes: Supplemental data

Journal Articles

Venous and arterial thrombosis in patients with VEXAS syndrome

Blood (2024) 143 (21): 2190–2200.

https://doi.org/10.1182/blood.2023022329

Published: 2024

Includes: Supplemental data

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias

Zhuoer Xie, Kristen McCullough, Terra L Lasho, Jenna A. Fernandez, Christy M Finke, Michelle Renee Amundson, Betsy LaPlant, Abhishek Mangaokar, Naseema Gangat, Kaaren K. Reichard, Michelle Ann Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2023-186595

Published: 2023

Journal Articles

Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1 -Integrated Molecular Models in Proliferative CMML

Clifford M Csizmar, Mark Gurney, Terra L Lasho, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle E. Hammond, Christy M Finke, Abhishek A Mangaonkar, Aref Al-Kali, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2023-186881

Published: 2023

Journal Articles

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2023-188328

Published: 2023

Journal Articles

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Blood (2023) 142 (Supplement 1): 321.

https://doi.org/10.1182/blood-2023-181795

Published: 2023

Journal Articles

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Blood (2023) 142 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2023-187860

Published: 2023

Journal Articles

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

Kristen McCullough, Omer Karrar, Moazah Iftikhar, Maymona Abdelmagid, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Mrinal M. Patnaik, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 5925.

https://doi.org/10.1182/blood-2023-182326

Published: 2023

Journal Articles

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Rory M. Shallis, Ondrej Blaha, Stephanie Halene, Lourdes Mendez, Nikolai A. Podoltsev, Anne Caldwell, Jan Philipp Bewersdorf, Richard F. Little, Richard Piekarz, Mrinal M. Patnaik, Steven D. Gore, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2023-182814

Published: 2023

Journal Articles

Distribution of Chromosome-Arm Specific Telomere Length in Patients with Telomere Biology Disorders

Alejandro Ferrer, Zachary D Stephens, Susan M. Geyer, Rachel A Simon, Terra L Lasho, Christy M Finke, Brittany Burnap, Lindsay A Mulvihill, Tammy M McAllister, Carolyn R. Rohrer Vitek, Konstantinos N Lazaridis, Angita Jain, Eric W Klee, Jean-Pierre A Kocher, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4103.

https://doi.org/10.1182/blood-2023-187486

Published: 2023

Journal Articles

STAG2 and PHF6 : Comparison of 2 X-Linked Gene Mutations in Myeloid Neoplasms

Bahga Katamesh, Amrutha Mittapalli, Rong He, David Viswanatha, Dragan Jevremovic, Mehrdad Hefazi, Antoine Saliba, Abhishek A Mangaonkar, Kebede Begna, William J. Hogan, Naseema Gangat, Mrinal M. Patnaik, Mithun V Shah, Ayalew Tefferi, Mark R. Litzow, Hassan Alkhateeb, Aref Al-Kali

Blood (2023) 142 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2023-178244

Published: 2023

Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood (2023) 142 (Supplement 1): 591.

https://doi.org/10.1182/blood-2023-178837

Published: 2023

Journal Articles

Targeting Oncogenic Enhancers in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Terra L Lasho, Christy M Finke, Jenna A. Fernandez, Christopher T. Schmitz, Karl J. Clark, Claes Wahlestedt, Judy Chiao, Abhishek A Mangaonkar, Mrinal M. Patnaik, Moritz Binder

Blood (2023) 142 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2023-178083

Published: 2023

Journal Articles

ASXL1 / TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

Clifford M Csizmar, Mark Gurney, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle E. Hammond, Terra L Lasho, Christy M Finke, Christopher Dean, Abhishek A Mangaonkar, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4615.

https://doi.org/10.1182/blood-2023-187235

Published: 2023

Journal Articles

Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes

Talha Badar, Terra L Lasho, Yael Kusne, Ludovica Marando, Abhishek A Mangaonkar, Christy M Finke, James M. Foran, Aref Al-Kali, Hassan Alkhateeb, Naseema Gangat, Rong He, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2023-187310

Published: 2023

Journal Articles

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Lih En Hong, Chung Hoow Kok, Monika Kutyna, Joule J Li, Rakchha Chhetri, David M. Ross, Susan Branford, Hamish S Scott, Anna Brown, Christopher Norman Hahn, David T Yeung, Mrinal M. Patnaik, Mithun V Shah, Susanna Proudman, Mihir Wechalekar, Devendra Hiwase

Blood (2023) 142 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2023-190809

Published: 2023

Journal Articles

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Blood (2023) 142 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2023-181673

Published: 2023

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

Venous and arterial thrombosis in patients with VEXAS syndrome

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias

Prognostic Relevance of Truncating ASXL1 Mutations and ASXL1 -Integrated Molecular Models in Proliferative CMML

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Distribution of Chromosome-Arm Specific Telomere Length in Patients with Telomere Biology Disorders

STAG2 and PHF6 : Comparison of 2 X-Linked Gene Mutations in Myeloid Neoplasms

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Targeting Oncogenic Enhancers in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

ASXL1 / TET2 Genotype-Based Risk Stratification Outperforms ASXL1 Mutational Impact and Is Independent of Mutant Variant Allele Fractions (VAF) in CMML

Clinical and Molecular Spectrum of Somatic Mosaic States in DDX41 mutant Germline Predisposition Syndromes

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only